A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
mortality
5 year after the last patients enrolled
5 year
Yes
Zhiwei Zhou, PHD
Study Chair
SunYat-sen University
China: Food and Drug Administration
SYSUCCGPS
NCT01795027
September 2011
June 2018
Name | Location |
---|